An Upgraded Review: Anti-Diabetic Medication administration by Liposomal Formulation

The prevalence of diabetes mellitus is increasing globally. Individuals suffering from diabetic complications encounter a range of social, mental, and physical challenges. Liposomes have been developed as a nanocarrier to enhance the administration of oral hypoglycaemic medications, surpassing the efficacy of conventional therapy. Liposomes offer significant regulation of raised blood glucose levels, rendering them a highly intriguing and potential therapeutic approach in contemporary research. Liposomes serve as a protective barrier for encapsulated hypoglycaemic medicines, hence optimising the efficacy of prolonged reductions in blood glucose levels. Hence, the objective of enhancing diabetes management while minimising the likelihood of both immediate and long-term complications is facilitated by the utilisation of liposomes filled with hypoglycaemic drugs. This article begins by examining the present condition of diabetes mellitus and the essential components of liposomal medicine delivery systems. We will next go into great detail about the composition, production methods, structure, along with drug incorporation of liposomes. In order to assure the efficiency of liposomes in both in vitro and in vivo settings, it is imperative to thoroughly characterise them prior to their utilisation. Consequently, numerous attributes of liposomes were examined. The primary objective of this review is to examine the limitations and stability of liposomes.